Abstract 73P
Background
Osimertinib(osi) has been established as standard of care for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (aNSCLC). FLOURISH is a real-world, multi-center, prospective, non-interventional study of first-line (1L) osi in Chinese patients(pts) with EGFRm aNSCLC. Here, we report the results of the post-progression analysis of the FLOURISH study.
Methods
Treatment naïve pts with locally advanced or metastatic EGFRm NSCLC were enrolled and received osi as 1L treatment. We evaluated post-progression clinical outcomes, including the progression sites, subsequent treatment, time to discontinuation of subsequent treatment (TTD2) and progression free survival after subsequent treatment (PFS2).
Results
The data cutoff date was April 27, 2024. Among the 481 pts in the full analytic set (FAS), 197 pts exhibited progression of disease, and only 142 pts reported progression sites. Lung was the most common sites of progression, affecting 95 out of 142 patients (66.9%). Notably, only 24 out of 142 (16.9%) pts experienced CNS progression. Among the 142 patients with disease progression, 91 (64.1%) pts received subsequent treatment. The median TTD2 was 29.8 months (95% CI: 25.5-NR), with 12, 24 and 36-month TTD2 rates of 13.3%, 31.5% and 54.7%, respectively. The median PFS2 was 25.7 months (95% CI: 24.3–29.7), with 12, 24 and 36-month PFS2 rates of 88.5%, 65.3% and 21.1%, respectively.
Conclusions
The FLOURISH study offers real-world insights into post-progression outcomes for Chinese pts with EGFRm aNSCLC treated with 1L osi. Lung was the most common progression site, while CNS progression was less frequent. The post-progression findings highlighted that 1L osi provided clinical benefit beyond initial progression for these pts in real-world setting and was consistent with previous studies.
Clinical trial identification
NCT04391283.
Legal entity responsible for the study
Guangdong Association of Clinical Trials.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.